- Home
- TSVT vs YMAB Comparison
TSVT vs YMAB Comparison
Compare TSVT & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSVT
- YMAB
- Stock Information
- Founded
- TSVT 2021
- YMAB 2015
- Country
- TSVT United States
- YMAB United States
- Employees
- TSVT N/A
- YMAB N/A
- Industry
- TSVT Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TSVT Health Care
- YMAB Health Care
- Exchange
- TSVT Nasdaq
- YMAB Nasdaq
- Market Cap
- TSVT 258.9M
- YMAB 218.4M
- IPO Year
- TSVT N/A
- YMAB 2018
- Fundamental
- Price
- TSVT $4.98
- YMAB $4.69
- Analyst Decision
- TSVT Buy
- YMAB Buy
- Analyst Count
- TSVT 4
- YMAB 11
- Target Price
- TSVT $6.50
- YMAB $18.73
- AVG Volume (30 Days)
- TSVT 1.1M
- YMAB 318.1K
- Earning Date
- TSVT 05-07-2025
- YMAB 05-06-2025
- Dividend Yield
- TSVT N/A
- YMAB N/A
- EPS Growth
- TSVT N/A
- YMAB N/A
- EPS
- TSVT N/A
- YMAB N/A
- Revenue
- TSVT $37,862,000.00
- YMAB $87,685,000.00
- Revenue This Year
- TSVT $84.48
- YMAB N/A
- Revenue Next Year
- TSVT $9.69
- YMAB $21.10
- P/E Ratio
- TSVT N/A
- YMAB N/A
- Revenue Growth
- TSVT N/A
- YMAB 3.38
- 52 Week Low
- TSVT $2.29
- YMAB $3.86
- 52 Week High
- TSVT $5.30
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- TSVT 76.79
- YMAB 47.75
- Support Level
- TSVT $4.88
- YMAB $4.46
- Resistance Level
- TSVT $4.99
- YMAB $5.44
- Average True Range (ATR)
- TSVT 0.03
- YMAB 0.45
- MACD
- TSVT -0.08
- YMAB 0.07
- Stochastic Oscillator
- TSVT 90.91
- YMAB 52.53
About TSVT 2seventy bio Inc.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.